Compare HWBK & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | IRWD |
|---|---|---|
| Founded | 1865 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.4M | 251.8M |
| IPO Year | N/A | 2010 |
| Metric | HWBK | IRWD |
|---|---|---|
| Price | $34.46 | $3.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.34 |
| AVG Volume (30 Days) | 11.3K | ★ 2.5M |
| Earning Date | 01-21-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 259.86 | N/A |
| EPS | ★ 3.19 | 0.18 |
| Revenue | $77,904,000.00 | ★ $338,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.01 |
| P/E Ratio | ★ $11.43 | $17.67 |
| Revenue Growth | ★ 45.83 | N/A |
| 52 Week Low | $25.21 | $0.53 |
| 52 Week High | $36.49 | $5.13 |
| Indicator | HWBK | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 50.16 |
| Support Level | $33.85 | $3.50 |
| Resistance Level | $36.25 | $3.84 |
| Average True Range (ATR) | 0.99 | 0.27 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 29.80 | 19.48 |
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.